Erratum: Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742) (Journal of Clinical Oncology (2018) DOI: 10.1200/JCO.2017.77.0388);Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)

Journal of Clinical Oncology

Volumn 36, Issue 14, 2018, Pages 1412-1418

  Ma, Brigette B Y ^a,b,c   Lim, Wan Teck ^d   Goh, Boon Cher ^e   Hui, Edwin P ^b,c   Lo, Kwok Wai ^b,c   Pettinger, Adam ^h   Foster, Nathan R ^h   Riess, Jonathan W ⁱ   Agulnik, Mark ^l   Chang, Alex Y C ^f   Chopra, Akhil ^g   Kish, Julie A ^m   Chung, Christine H ^m   Adkins, Douglas R ⁿ   Cullen, Kevin J ^o   Gitlitz, Barbara J ^j   Lim, Dean W ^k   To, Ka Fai ^b,c   Chan, K C Allen ^b,c   Lo, Y M Dennis ^b,c   King, Ann D ^b,c   Erlichman, Charles ^h   Yin, Jun ^h   Costello, Brian A ^h   Chan, Anthony T C ^b,c   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Special Administrative Region ^*  (China)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e National University Cancer Institute   (Singapore)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Oncocare Cancer Centre   (Singapore)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF MARYLAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; VIRUS DNA; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT LOSS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLITIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; LOG RANK TEST; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MEDICATION COMPLIANCE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PUSTULE; RASH; SEPSIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL CARCINOMA; NEOPLASM RECURRENCE, LOCAL; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85047156113     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2018.79.3349     Document Type: Erratum

References (35)

1. Lo YM, Leung SF, Chan LY, et al: Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60:2351-2355, 2000
2. Chen BJ, Chapuy B, Ouyang J, et al: PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19:3462-3473, 2013
3. Lin DC, Meng X, Hazawa M, et al: The genomic landscape of nasopharyngeal carcinoma. Nat Genet 46:866-871, 2014
4. Li YY, Chung GT, Lui VW, et al: Exome and genome sequencing of nasopharynx cancer identifies NF-kB pathway activating mutations. Nat Commun 8:14121, 2017
5. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multi-centre, open-label, phase 1b trial. Lancet Oncol 17: 717-726, 2016
6. Garrido F, Ruiz-Cabello F, Aptsiauri N: Rejection versus escape: The tumor MHC dilemma. Cancer Immunol Immunother 66:259-271, 2017
7. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
8. Lim WT, Ng QS, Ivy P, et al: A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 17: 5481-5489, 2011
9. Chan AT, Hsu MM, Goh BC, et al: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23: 3568-3576, 2005
10. Hoos A: Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15:235-247, 2016
11. Champiat S, Dercle L, Ammari S, et al: Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23:1920-1928, 2017
12. Wang CC, Chang JY, Liu TW, et al: Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck 28:74-80, 2006
13. Zhang Y, Zhao L, Huang P, et al: Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Cancer Chemother Pharmacol 70:611-615, 2012
14. Hui EP, Ma BBY, Loong H, et al: Efficacy, safety and pharmacokinetics of axitinib in nasopharyngeal carcinoma: A preclinical and phase 2 correlative study. Clin Cancer Res 24:5 2018
15. Hsu C, Lee SH, Ejadi S, et al: Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol 35:4050-4056, 2017
16. Fang W, Zhang J, Hong S, et al: EBV-driven LMP1 and IFN-g up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 5:12189-12202, 2014
17. Chan OS, Kowanetz M, Ng WT, et al: Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncol 67: 52-60, 2017
18. Zhu Q, Cai MY, Chen CL, et al: Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology 6:e1312240, 2017
19. Kluger HM, Zito CR, Turcu G, et al: PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clin Cancer Res 23: 4270-4279, 2017
20. Ferris RL, Blumenschein G, Jr., Fayette J, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867, 2016
21. Chow LQM, Haddad R, Gupta S, et al: Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838-3845, 2016
22. Thompson RH, Gillett MD, Cheville JC, et al: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104: 2084-2091, 2005
23. Grigg C, Rizvi NA: PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction? J Immunother Cancer 4:48, 2016
24. López-Nevot MA, Esteban F, Ferrón A, et al: HLA class I gene expression on human primary tumours and autologous metastases: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221-226, 1989
25. Šmahel M: PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int J Mol Sci 18:1331, 2017
26. Inoue H, Park JH, Kiyotani K, et al: Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. OncoImmunology 5:e1204507, 2016
27. Johnson DB, Estrada MV, Salgado R, et al: Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7: 10582, 2016
28. Hugo W, Zaretsky JM, Sun L, et al: Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35-44, 2016
29. Zaretsky JM, Garcia-Diaz A, Shin DS, et al: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819-829, 2016
30. Roemer MG, Advani RH, Redd RA, et al: Classical Hodgkin lymphoma with reduced b2M/
31. MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res 4:910-916, 2016
32. Kim JM, Chen DS: Immune escape to PD-L1/ PD-1 blockade: Seven steps to success (or failure). Ann Oncol 27:1492-1504, 2016
33. Beldi-Ferchiou A, Lambert M, Dogniaux S, et al: PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7:72961-72977, 2016
34. Pesce S, Greppi M, Tabellini G, et al: Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol 139:335-346.e3, 2017
35. Chan KC, Chan AT, Leung SF, et al: Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 51:2192-2195, 2005